Overall (N=147) | Children (N=68) | Adults (N=79) | PFS subtypes | ||||
---|---|---|---|---|---|---|---|
CAPS (N=59) | TRAPS (N=40) | HIDS/MKD (N=11) | FMF (N=42) | ||||
Age when first prescribed canakinumab (years), mean (SD) | 20.7 (15.9) | 9.1 (4.3) | 30.7 (15.5) | 22.9 (17.8) | 20.4 (14.6) | 19.8 (19.4) | 17.4 (12.3) |
Year of canakinumab initiation, n (%) | |||||||
2016 | 8 (5.4) | 2 (2.9) | 6 (7.6) | 4 (6.8) | 1 (2.5) | 0 (0.0) | 3 (7.1) |
2017 | 58 (39.5) | 27 (39.7) | 31 (39.2) | 26 (44.1) | 15 (37.5) | 5 (45.5) | 15 (35.7) |
2018 | 81 (55.1) | 39 (57.4) | 42 (53.2) | 29 (49.2) | 24 (60.0) | 6 (54.5) | 24 (57.1) |
Canakinumab initial dose (reported by physician as mg/kg or calculated mg/kg when weight was available), mean (SD) | 2.8 (1.8) [N=144] | 3.3 (2.2) [N=67] | 2.3 (1.1) [N=77] | 3.0 (2.2) [N=57] | 2.3 (0.7) [N=40] | 2.4 (1.3) [N=10] | 3.0 (1.8) [N=41] |
Initial dose among physicians who reported mg/kg, mean (SD) | 2.9 (1.9) [N=67] | 2.9 (2.0) [N=47] | 2.9 (1.5) [N=20] | 3.3 (2.3) [N=27] | 2.0 (0.0) [N=12] | 2.2 (0.4) [N=6] | 3.0 (1.7) [N=24] |
Initial dose among physicians who reported mg | N=80 | N=21 | N=59 | N=32 | N=28 | N=5 | N=18 |
Mean (SD) | 134.2 (46.9) | 123.3 (38.1) | 138.1 (49.4) | 138.7 (54.0) | 134.8 (39.3) | 112.4 (60.2) | 133.9 (38.5) |
Median (Q1, Q3) | 150.0 (150.0, 150.0) | 150.0 (100.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (150.0, 150.0) | 150.0 (100.0, 150.0) | 150.0 (150.0, 150.0) |
Initial frequency, n (%) | |||||||
Every 4 weeks | 73 (49.7) | 36 (52.9) | 37 (46.8) | 19 (32.2) | 23 (57.5) | 6 (54.5) | 26 (61.9) |
Every 8 weeks | 74 (50.3) | 32 (47.1) | 42 (53.2) | 40 (67.8) | 17 (42.5) | 5 (45.5) | 16 (38.1) |
Received concomitant treatment with another long- or short-term PFS medication (including biologics), n (%) | |||||||
Yes | 67 (45.6) | 29 (42.6) | 38 (48.1) | 26 (44.1) | 20 (50.0) | 5 (45.5) | 18 (42.9) |
No | 80 (54.4) | 39 (57.4) | 41 (51.9) | 33 (55.9) | 20 (50.0) | 6 (54.5) | 24 (57.1) |